Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: RETRACTED ARTICLE: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

Fig. 4

Regulation of EAhy926 cell migration and B16F10 and MDA-MB-231 cell invasion by HM-3 and Sunitinib. EAhy926 cell migration and B16F10 and MDA-MB-231 cell invasion were assayed using the transwell method. 0.1 ml EAhy926 cell suspension (1 × 105 cells/ml), B16F10 cell suspension (5 × 105 cells/ml) or MDA-MB-231 (5 × 105 cells/ml) cell suspension were added to Matrigel-coated transwells. HM-3 or Sunitinib were present in the upper solution at different concentrations. Endostatin (ES, 0.4 μM) was used as a positive control reagent. The cell migration tests were performed at 37 °C for 24 h. a Typical microphotographs of the migrated EAhy926 cells in the presence of Sunitinib at indicated concentrations. Migrated cells are colored purple, while cells without migration are transparent. Numbers of migrated cells (b) and percent inhibition of migration (c) are shown. Percent inhibition by Sunitinib (d) and HM-3 (e) in B16F10 cell invasion. Percent inhibition of Sunitinib (f) and HM-3 (g) in MDA-MB-231 cell invasion. In each case, HM-3 or Sunitinib inhibited cell migration or invasion at low doses and promoted cell migration or invasion at high doses (*P < 0.05, **P < 0.01)

Back to article page